Clinical characteristics of the RS series
| Characteristics . | Number/available data . | % . | 95% CI . |
|---|---|---|---|
| Clinical features at RS diagnosis | |||
| Age >60 y | 29/41 | 70 | 54-84 |
| Male | 24/43 | 56 | 39-71 |
| ECOG PS > 1 | 10/19 | 52 | 29-76 |
| Ann Arbor stage III-IV | 38/39 | 97 | 86-99 |
| Binet stage | 20 | ||
| A | 4/20 | 20 | 6-44 |
| B | 8/20 | 40 | 19-64 |
| C | 8/20 | 40 | 19-64 |
| B symptoms | 13/28 | 46 | 27-66 |
| Extranodal sites >1 | 8/26 | 31 | 14-52 |
| Tumor size >5 cm | 16/34 | 47 | 30-65 |
| Nodal areas >5 | 11/28 | 39 | 21-59 |
| ALC >5.0 × 109/L | 12/27 | 44 | 25-65 |
| Hb < 10 g/dL | 11/30 | 37 | 20-56 |
| Platelets < 100 × 109/L | 7/29 | 24 | 10-43 |
| LDH > 1.5 ULN | 14/28 | 50 | 31-69 |
| CD38 expression | 12/26 | 46 | 27-67 |
| ZAP70 expression | 11/18 | 61 | 36-83 |
| Previous CLL therapies >1 | 17/22 | 77 | 54-92 |
| Pathologic features at RS diagnosis | |||
| Non-GC phenotype* | 25/25 | 100 | 87-100 |
| CD10 expression | 0/27 | 0 | 0-13 |
| BCL6 expression | 9/24 | 38 | 19-55 |
| MUM1 expression | 21/22 | 95 | 77-100 |
| CD5 expression† | 10/13 | 77 | 46-95 |
| CD23 expression† | 12/15 | 80 | 52-96 |
| MYC translocation‡ | 3/17 | 18 | 4-43 |
| TP53 mutations‡ | 12/20 | 60 | 36-81 |
| Ki-67+>70% | 14/30 | 47 | 28-66 |
| CLL treatment previous to RS | |||
| Fludarabine-based regimens | 14/22 | 64 | 41-83 |
| Previous alkylating agents | 12/22 | 55 | 32-76 |
| RS treatment | |||
| Rituximab chemotherapy | 18/28 | 64 | 44-81 |
| CHOP-based treatment | 19/28 | 68 | 48-84 |
| NHL second-line regimens | 2/28 | 7 | 9-23 |
| Allogeneic stem cell transplant | 2/28 | 7 | 9-23 |
| Characteristics . | Number/available data . | % . | 95% CI . |
|---|---|---|---|
| Clinical features at RS diagnosis | |||
| Age >60 y | 29/41 | 70 | 54-84 |
| Male | 24/43 | 56 | 39-71 |
| ECOG PS > 1 | 10/19 | 52 | 29-76 |
| Ann Arbor stage III-IV | 38/39 | 97 | 86-99 |
| Binet stage | 20 | ||
| A | 4/20 | 20 | 6-44 |
| B | 8/20 | 40 | 19-64 |
| C | 8/20 | 40 | 19-64 |
| B symptoms | 13/28 | 46 | 27-66 |
| Extranodal sites >1 | 8/26 | 31 | 14-52 |
| Tumor size >5 cm | 16/34 | 47 | 30-65 |
| Nodal areas >5 | 11/28 | 39 | 21-59 |
| ALC >5.0 × 109/L | 12/27 | 44 | 25-65 |
| Hb < 10 g/dL | 11/30 | 37 | 20-56 |
| Platelets < 100 × 109/L | 7/29 | 24 | 10-43 |
| LDH > 1.5 ULN | 14/28 | 50 | 31-69 |
| CD38 expression | 12/26 | 46 | 27-67 |
| ZAP70 expression | 11/18 | 61 | 36-83 |
| Previous CLL therapies >1 | 17/22 | 77 | 54-92 |
| Pathologic features at RS diagnosis | |||
| Non-GC phenotype* | 25/25 | 100 | 87-100 |
| CD10 expression | 0/27 | 0 | 0-13 |
| BCL6 expression | 9/24 | 38 | 19-55 |
| MUM1 expression | 21/22 | 95 | 77-100 |
| CD5 expression† | 10/13 | 77 | 46-95 |
| CD23 expression† | 12/15 | 80 | 52-96 |
| MYC translocation‡ | 3/17 | 18 | 4-43 |
| TP53 mutations‡ | 12/20 | 60 | 36-81 |
| Ki-67+>70% | 14/30 | 47 | 28-66 |
| CLL treatment previous to RS | |||
| Fludarabine-based regimens | 14/22 | 64 | 41-83 |
| Previous alkylating agents | 12/22 | 55 | 32-76 |
| RS treatment | |||
| Rituximab chemotherapy | 18/28 | 64 | 44-81 |
| CHOP-based treatment | 19/28 | 68 | 48-84 |
| NHL second-line regimens | 2/28 | 7 | 9-23 |
| Allogeneic stem cell transplant | 2/28 | 7 | 9-23 |
ALC, absolute lymphocyte count; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CI, confidence interval; CR, complete remission; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GC, germinal center; LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; ULN, upper limit of normal.
According to Hans et al19 with immunohistochemistry performed locally during the diagnostic procedure.
With immunohistochemistry performed locally during the diagnostic procedure.
From Rossi et al.3